Boehringer Ingelheim India and RED.Health ambulance services sign MOU to strengthen emergency stroke care in pre-hospital setup in India.

India,

Boehringer Ingelheim India and RED.Health ambulance services sign MOU to strengthen emergency stroke care in pre-hospital setup in India.

Boehringer Ingelheim India, through its Angels Initiative signed a Memorandum of Understanding (MoU) with RED.Health, the emergency care expert, to strengthen emergency pre-hospital stroke care services in India. This collaboration underscores a shared commitment to advancing emergency healthcare and supporting timely, life-saving medical interventions. The MoU was signed just ahead of World Stroke Day, reinforcing both organizations' commitment to advancing stroke care and add value to Stroke Care Eco-system in country.

India is currently witnessing a rise in stroke cases, and according to data, stroke is now the fourth leading cause of death and the fifth leading cause of disability.[i] Despite its prevalence, many patients arrive at the hospital after the critical "golden period," reducing their chances of receiving effective treatment. It is important that a patient receives treatment within the golden period of 4.5 hours from the onset of symptoms. This partnership aims to change that by focusing on faster response times, comprehensive training, and the seamless integration of advanced medical protocols in pre-hospital settings. With the implementation of standardized stroke protocols and enhanced EMT training, the initiative is poised to deliver better health outcomes in Stroke care journey. 

"We believe that organized, timely intervention can transform stroke outcomes. The collaboration with RED.Health Ambulance Services strengthens emergency stroke care and ensuring every patient receives rapid, high-quality assistance.  Together, we are building a healthcare system that puts patients at the heart of healthcare and raise hope for families across India, said Gagandeep Singh Bedi, Managing Director, Boehringer Ingelheim India.

Prabhdeep Singh, Founder and CEO, RED.Health, added, “Stroke impacts over 1.9 million people across India annually, and timely intervention is crucial for saving lives and improving outcomes. At RED.Health, we are committed to delivering fast, reliable, and compassionate emergency care when it matters most. Partnering with Boehringer Ingelheim enhances our ability to respond swiftly and effectively to stroke cases nationwide. This MoU represents a significant step in empowering our emergency response teams with advanced training and protocols, reaffirming our dedication to elevating emergency medical services and extending vital, life-saving support to communities across the country.”

The MOU includes the implementation of formal stroke protocols for RED.Health ambulances and the utilization of specific stroke scales like FAST (Face, Arm, Speech, Time)[ii] during patient transport. Furthermore, all training and support provided by the Angels Initiative will be at no financial cost to RED.Health, underscoring the shared commitment to improving emergency medical care in Country. In addition, RED.Health will gain access to advanced stroke life support and emergency medical service certification programs via the Angels Initiative platform, enhancing the capabilities of their emergency response teams. RED.Health Ambulance will also participate in EMS Angels Awards for their Quality monitoring through Stroke registry on Stroke patients' delivery. 

 

About Red Health Ambulance

Established in 2016, RED.Health has been redefining the ambulance service industry by making it more accessible and affordable for millions. RED.Health is a prominent provider of emergency medical response solutions, dedicated to delivering timely and efficient care to patients in critical conditions. With a network of highly trained EMTs and state-of-the-art medical equipment, RED.Health is committed to saving lives and improving healthcare delivery across India.

About Boehringer Ingelheim

Boehringer Ingelheim, a leading biopharmaceutical company founded in 1885, develops breakthrough therapies for humans and animals. With 53,000 employees, it operates in over 130 markets, focusing on Human Pharma, Animal Health, and Biopharmaceutical Contract Manufacturing. Established in 2003, Boehringer Ingelheim India manages operations in India and neighbouring markets, offering innovative products in Human Pharma and Animal Health, with key therapy areas including diabetes, cardiovascular, and respiratory conditions. Learn more at https://www.boehringer-ingelheim.com/in


[i] (Ref: Jones SP, et al. International Journal of Stroke. 2022;17(2):132-140)

[ii] Recognise A Stroke With FAST | Boehringer Ingelheim IN

Media Contacts